Cognitive training program for patients with schizophrenia
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
NA · Centre hospitalier de Ville-Evrard, France · NCT04608032
This study tests a new cognitive training program for people with schizophrenia to see if it helps improve their thinking and social skills better than standard therapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Centre hospitalier de Ville-Evrard, France (other) |
| Locations | 2 sites (Neuilly-sur-Marne and 1 other locations) |
| Trial ID | NCT04608032 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of an ecological cognitive remediation program designed for patients with schizophrenia spectrum disorders. It compares the cognitive training program to recovery-oriented therapy in a double-blind, controlled, randomized format. Patients will receive treatment for two months and will be monitored for four months to assess improvements in neurocognitive, social cognitive, and metacognitive functions. The goal is to determine the specific therapeutic efficacy of the cognitive remediation program.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with schizophrenia who have stable symptoms and cognitive complaints.
Not a fit: Patients with other psychiatric diagnoses or those experiencing acute episodes may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve cognitive functions in patients with schizophrenia, enhancing their quality of life.
How similar studies have performed: Previous studies have shown promise in cognitive remediation for schizophrenia, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Schizophrenia Disorder diagnosis, according to Diagnostic and Statistical Manual of mental disorders - Fifth edition (DSM-V) - Patient stabilized in terms of positive and negative symptomatology (absence or presence of weak positive and negative symptoms) * Positive and Negative stable symptoms (no or few positive and negative symptoms) * Stable and effective minimum dose of medication (antipsychotic) for the last three months * Cognitive complaint expressed by the patient * Informed consent form read, initialed and signed * Understanding of spoken and read French * Patient registered on the social welfare system Exclusion Criteria: * Other diagnosis at the forefront than Schizophrenia of the DSM-V * Medical history neurological disorder resulting in hospitalization * Acute episode in the last three month * Somatic disorders resulting in cognitive impairment * Engagement in a research protocol either currently or over the last month * Neuropsychological assessment evaluation during the last six month * Patients under the protection of a conservator (simple or reinforced) * Individuals in vulnerable circumstances
Where this trial is running
Neuilly-sur-Marne and 1 other locations
- Ch Ville Evrard — Neuilly-sur-Marne, France (RECRUITING)
- URC Ville Evrard — Neuilly-sur-Marne, France (RECRUITING)
Study contacts
- Principal investigator: Clémence ISAAC, PHD — URC EPS Ville Evrard
- Study coordinator: Dominique JANUEL, MBBS
- Email: d.januel@epsve.fr
- Phone: 0143093232
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Schizophrenic Disorders, Schizophrenia, Neurocognition, Social cognition, Metacognition, Cognitive remediation